Dr Marian Schini

MD, PhD, FHEA

School of Medicine and Population Health

Senior Clinical Research Fellow in Bone Metabolism

Marian Schini
Dr Marian Schini
Profile picture of Marian Schini
m.schini@sheffield.ac.uk
+44 114 215 9698
Metabolic Bone Centre Sorby Wing, Northern General Hospital

Full contact details

Dr Marian Schini
School of Medicine and Population Health
Metabolic Bone Centre Sorby Wing
Northern General Hospital
Herries Road
Sheffield
S5 7AU
Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I graduated from the Medical school of the University of Patras in Greece in 2005. After 4 years of training in Internal Medicine and 4 years in Endocrinology and Diabetes, I successfully obtained my CCT in Endocrinology and Diabetes in 2014. I have been working as a clinical research fellow for the University of Sheffield since 2015, with an interest in osteoporosis and calcium metabolism disorders. During this time, I undertook a PhD focusing on the prevalence and natural history of normocalcaemic hyperparathyroidism and hypoparathyroidism, two disorders of calcium metabolism. This project was funded by The Medical Research Council Versus Arthritis Centre for Integrated Research into Musculoskeletal Ageing and the Osteoporosis 2000 Support Group.

After completing my PhD in 2020, I was appointed as an NHS consultant at the Metabolic Bone Centre at Sheffield Teaching Hospitals, but maintained my role as a fellow with the University of Sheffield, to pursue my research interest in bone metabolism further.

I have been involved in several research projects in collaboration with researchers from the University of Sheffield, national but also international higher institutions. These projects have led to a number of publications and awards. I am the primary investigator for the POSE study (PINP and Osteoporosis in Sheffield Evaluation), a project aiming to investigate the use of PINP to monitor osteoporosis treatment in clinical practice by non-specialist practitioners. I am also the lead investigator in studies evaluating current osteoporosis treatments further, like denosumab and zoledronic acid. I have supported and continue to support a number of clinical trials as both a primary and sub-investigator. Some of these studies are on rare disorders of bone metabolism like X-linked hypophosphataemia and osteogenesis imperfecta, for which I have developed a special interest.

Research interests

My research interests are osteoporosis, calcium metabolism disorders and rare bone metabolism disorders like X-linked hypophosphataemia and hypophosphatasia.

My PhD work was around the prevalence and natural history of normocalcaemic hyperparathyroidism and hypoparathyroidism. This project provided some further understanding of these two newly described conditions which can help in their monitoring and treatment. Due to my interest and growing experience in these disorders, I was asked to assist in preparing the next international guidelines on normocalcaemic hyperparathyroidism

I was also involved in a number of systematic reviews and meta-analyses to evaluate the risk of fractures in patients with different chronic conditions like Parkinson’s disease and diabetes mellitus. These studies were performed in collaboration with ScHARR and the team of Dr Steve Cummings in the University of California.

Throughout the years, I provided support and continue to support various clinical trials around bone metabolism like:

  • Primary investigator in the clinical trial: ‘The BUR02 study: A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH)
  • Sub-investigator in the clinical trial “TOPaZ: Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acidâ€
  • Sub-investigator in the clinical trial “The STAG Study: Phase II Study of the Impact of AZD4017, A Selective 11β-HSD1 Inhibitor, on Biochemical Markers of Bone Turnover in Post-Menopausal Osteopeniaâ€
  • Sub-investigator in the clinical trial “AXLES: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH)â€
  • Sub-investigator in the “SeMS study: Double-blind, randomised, placebo-controlled trial on the effect of selenium supplementation on musculoskeletal health in older womenâ€
Publications

Show: Featured publications All publications

Journal articles

  • Fontalis A, Gossiel F, Schini M, Walsh J & Eastell R (2020) . Bone Reports, 13.
  • Schini M, Jacques R, Oakes E, Peel N, Walsh J & Eastell R (2020) . The Journal of Clinical Endocrinology & Metabolism, 105(4).

All publications

Journal articles

  • McCloskey EV, Johansson H, Liu E, Ã…kesson KE, Anderson FA, Azagra-Ledesma R, Bager CL, Beaudart C, Bischoff-Ferrari HA, Biver E , Bruyère O et al (2025) . Osteoporosis International.
  • Lorentzon M, Johansson H, Harvey NC, Liu E, Schini M, Vandenput L, McCloskey E & Kanis JA (2025) . Osteoporosis International, 36(9), 1749-1751.
  • Vilaca T, Lui L-Y, Schini M, Ewing SK, Thompson A, Vittinghoff E, Bauer DC, Black DM, Bouxsein ML & Eastell R (2025) . Journal of Bone and Mineral Research.
  • Zoulakis M, Johansson H, Harvey NC, Axelsson KF, Litsne H, Johansson L, Schini M, Vandenput L, McCloskey EV, Kanis JA & Lorentzon M (2025) . Osteoporosis International, 36(9), 1649-1659.
  • Kanis JA, Johansson H, McCloskey EV, Liu E, Schini M, Vandenput L, Ã…kesson KE, Anderson FA, Azagra R, Bager CL , Beaudart C et al (2025) . Osteoporosis International, 36(4), 653-671.
  • Song K, Vijjhalwar R, Aye M, Comninos AN, Schini M, Abbas A, Gittoes N & Javaid MK (2025) . Journal of the Endocrine Society, 9(2).
  • Tan ATH, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey E & Schini M (2025) . Gaceta Médica de México, 160(4).
  • Schini M, Lui L-Y, Vilaca T, Ewing SK, Thompson A, Bauer DC, Bouxsein ML, Black DM & Eastell R (2025) . Journal of Bone and Mineral Research, 40(3), 307-314.
  • Schini M, Gossiel F, Saini T, Banda P, Ward R, Vilaca T, Eastell R & Fontalis A (2025) . Journal of Bone and Mineral Research, 40(3).
  • Tan ATH, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey E & Schini M (2024) . Gaceta Médica de México, 160(4), 363-373.
  • Vilaca T, Toronjo Schini M, Thompson AR, Vittinghoff E, Lui L-Y, Ewing SK, Bauer DC, Black DM, Bouxsein M & Eastell R (2024) . Journal of the Endocrine Society, 8(Supplement_1).
  • Vilaca T, Schini M, Lui L-Y, Ewing SK, Thompson AR, Vittinghoff E, Bauer DC, Eastell R, Black DM & Bouxsein ML (2024) . Journal of Bone and Mineral Research, 39(10), 1434-1442.
  • Kanis JA, Harvey NC, Lorentzon M, Liu E, Schini M, Abrahamsen B, Adachi JD, Alokail M, Borgstrom F, Bruyère O , Carey JJ et al (2024) . Osteoporosis International, 35(9), 1487-1496.
  • McCloskey E, Tan ATH & Schini M (2024) . Current Opinion in Endocrinology, Diabetes & Obesity, 31(4), 141-148.
  • Schini M, Vilaca T, Lui L-Y, Ewing SK, Thompson A, Vittinghoff E, Bauer DC, Bouxsein ML, Black DM & Eastell R (2024) . Journal of Bone and Mineral Research, 39(7), 867-876.
  • Schini M, Vilaca T, Vittinghoff E, Lui L-Y, Ewing SK, Thompson AR, Bauer DC, Bouxsein ML, Black DM & Eastell R (2024) . Journal of Bone and Mineral Research, 39(5), 544-550.
  • Vandenput L, Johansson H, McCloskey EV, Liu E, Schini M, Ã…kesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C , Bischoff-Ferrari HA et al (2024) . Osteoporosis International, 35(3), 469-494.
  • Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA & McCloskey EV (2024) . Journal of Endocrinological Investigation, 47, 501-511.
  • Albergaria BH, Zerbini CAF, Lazaretti-Castro M, Eis SR, Vilaca T, Johansson H, Harvey NC, Liu E, Vandenput L, Lorentzon M , Schini M et al (2023) . Archives of Osteoporosis, 18(1).
  • Schini M, Bhatia P, Shreef H, Johansson H, Harvey NC, Lorentzon M, Kanis JA, Bandmann O & McCloskey EV (2023) . Bone, 168.
  • Schini M, Vilaca T, Gossiel F, Salam S & Eastell R (2023) . Endocrine Reviews, 44(3), 417-473.
  • Abbas A, Schini M, Ainsworth G, Brown SR, Oughton J, Crowley RK, Cooper MS, Fairclough RJ, Eastell R & Stewart PM (2022) . Journal of Clinical Endocrinology and Metabolism, 107(7), 2026-2035.
  • Vilaca T, Eastell R & Schini M (2022) . Lancet Diabetes & Endocrinology, 10(4), 273-283.
  • Mattia L, Davis S, Mark-Wagstaff C, Abrahamsen B, Peel N, Eastell R & Schini M (2022) . Bone, 158.
  • Orlando G, Bubbear J, Clarke S, Keen R, Roy M, Anilkumar A, Schini M, Walsh JS, Javaid MK & Ireland A (2022) . Osteoporosis International, 33(7), 1485-1491.
  • Schini M, Peel N, Toronjo-Urquiza L, Thomas E, Salam S, Khwaja A, Eastell R & Walsh JS (2022) . Osteoporosis International, 33(3), 737-744.
  • Orlando G, Clarke S, Roy M, Lachmann R, Walsh J, Schini M, Kassim J & Ireland A (2021) . Bone Reports, 14.
  • Umarji PB, Verma P, Garg V, Schini M & Eastell R (2021) . Nutrients, 13(2).
  • Schini M, Hannan FM, Walsh JS & Eastell R (2021) . Clinical Endocrinology, 94(1), 34-39.
  • Schini M, Jacques R, Oakes E, Peel N, Walsh JS & Eastell R (2021) . European Journal of Endocrinology, 184(1), K7-K10.
  • El-Hajj Fuleihan G, Chakhtoura M, Cipriani C, Eastell R, Karonova T, Liu J-M, Minisola S, Mithal A, Moreira CA, Peacock M , Schini M et al (2020) . Journal of Bone and Mineral Research, 37(11), 2330-2350.
  • Schini M, Nicklin P & Eastell R (2020) . Bone, 141.
  • Schini M, Hannan F, Walsh J & Eastell R (2020) . Bone Reports, 13.
  • Fontalis A, Gossiel F, Schini M, Walsh J & Eastell R (2020) . Bone Reports, 13.
  • Vilaca T, Salam S, Schini M, Harnan S, Sutton A, Poku E, Allen IE, Cummings SR & Eastell R (2020) . American Journal of Kidney Diseases, 76(4), 521-532.
  • Schini M, Stirling R, Jacques R, Oakes E, Peel N, Walsh J & Eastell R (2020) . Clinical Endocrinology, 93(2), 119-126.
  • Vilaca T, Schini M, Harnan S, Sutton A, Poku E, Allen IE, Cummings SR & Eastell R (2020) . Bone, 137.
  • Schini M & Eastell R (2020) . The Journal of Clinical Endocrinology & Metabolism, 105(7).
  • Schini M, Jacques R, Oakes E, Peel N, Walsh J & Eastell R (2020) . The Journal of Clinical Endocrinology & Metabolism, 105(4).
  • Schini M, Vilaca T, Poku E, Harnan S, Sutton A, Allen IE, Cummings SR & Eastell R (2020) . Bone, 132.
  • Makras P, Salagianni M, Revelos K, Anastasilakis AD, Schini M, Tsoli M, Kaltsas G & Andreakos E (2015) . The Journal of Clinical Endocrinology & Metabolism, 100(2), E282-E286.
  • Striki A, Manolakopoulos S, Deutsch M, Mela M, Kalafateli M, Schini M, Anagnostou O, Triantos C, Andreadis I, Ketikoglou I , Papatheodoridis G et al (2014) . Journal of Viral Hepatitis, 21(9), 624-632.
  • Schini M, Makras P, Kanakis G, Voulgarelis M & Kaltsas G (2013) . Leukemia & Lymphoma, 54(7), 1541-1543.
  • Mavragani CP, Schini M, Gravani F, Kaltsas G & Moutsopoulos HM (2012) . Arthritis & Rheumatism, 64(12), 4066-4071.
  • Makras P, Polyzos SA, Anastasilakis AD, Terpos E, Kanakis G, Schini M, Papatheodorou A & Kaltsas GA (2012) . The Journal of Clinical Endocrinology & Metabolism, 97(4), E618-E621.
  • Bubbear J, Lachmann R, Murphy E, Krishna G, Clunie GPR, Walsh J, Schini M, Salam S, Roy M, Finezilber Y , Mathieson L et al () . Calcified Tissue International, 116(1).
  • Neelam-Naganathan D, Komber A, Eastell R & Schini M () . Endocrine Abstracts.
  • Elamin A, Schini M, Eastell R & Debono M () . Endocrine Abstracts.
  • Schini M () . Endocrine Abstracts.

Conference proceedings

  • Bubbear J, Lachmann R, Murphy E, Krishna G, Clunie G, Walsh J, Schini M, Salam S, Roy M, Mathieson L , Hayes V et al (2024) Patient reported outcomes (PROs) from a real-world study of burosumab treatment in adults with X-linked hypophosphatemia (XLH) in the UK. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 39 (pp 69-69)
  • Harvey NC, Kanis JA, Johansson H, McCloskey EV, Liu E, Schini M, Vandenput L, Lorentzon M & Leslie WD (2024) Is The Predictive Value of Rheumatoid Arthritis for Incident Fracture Dependent On Age, Sex, BMD or Follow-Up Time? An International MetaAnalysis of 1.6 Million Participants. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 39 (pp 380-380)
  • Vilaca T, Lui L-YL, Schini M, Ewing SK, Thompson AR, Vittinghoff E, Bauer DC, Black DM, Bouxsein ML & Eastell R (2024) Treatment-related changes in total hip bone mineral density and fracture risk reduction for trials with active control and sequential therapy: the FNIH-ASBMR-SABRE Project. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 39 (pp 52-52)
  • Schini M, Kado DM, Lui L-YL, Ewing SK, Vilaca T, Thompson AR, Bouxsein ML, Eastell R & Black DM (2024) Efficacy of Anti-Osteoporosis Therapy in Women Under and Over Age 75: an Analysis of the FNIH-ASBMR-SABRE Database. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 39 (pp 210-211)
  • Schini M, Lui L-YL, Vilaca T, Ewing SK, Thompson AR, Vittinghoff E, Bauer DC, Bouxsein ML, Black DM & Eastell R (2024) Relationship between baseline BMD and fracture risk in the placebo groups from the FNIH-ASBMR-SABRE Project. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 39 (pp 365-365)
  • McCloskey EV, Johansson H, Liu E, Schini M, Vandenput L, Harvey NC, Lorentzon M, Leslie WD & Kanis JA (2024) FAMILY HISTORY OF FRACTURE AND FRACTURE RISK: A META-ANALYSIS TO UPDATE THE FRAX® RISK ASSESSMENT TOOL. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 36 (pp S25-S26)
  • Zoulakis M, Johansson H, Harvey NC, Axelsson KF, Litsne H, Johansson L, Liu E, Schini M, Vandenput L, McCloskey EV , Kanis JA et al (2024) EFFECT OF FRAXPLUS ADJUSTMENTS ON FRACTURE RISK RECLASSIFICATION IN OLDER SWEDISH WOMEN-RESULTS FROM THE SUPERB-STUDY. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 36 (pp S22-S23)
  • Vilaca T, Schini M, Vittinghoff E, Lui L-Y, Ewing S, Bauer D, Bouxsein M, Eastell R & Black D (2023) The association between treatment-related differences in total hip bone mineral density change and fracture risk reduction for BMD measurement intervals of 12, 18 and 24 months: the FINH-ASBMR SABRE Project. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 240-240)
  • Schini M, Vilaca T, Vittinghoff E, Lui L-Y, Ewing S, Bauer D, Black D, Bouxsein M & Eastell R (2023) Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: Results from the FNIH-ASBMR SABRE Project. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 66-66)
  • Schini M, Vilaca T, Vittinghoff E, Lui L-Y, Ewing S, Bauer D, Black D, Bouxsein M & Eastell R (2023) Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: Results from the FNIH-ASBMR SABRE Project. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 10-11)
  • Vandenput L, Johansson H, McCloskey EV, Liu E, Schini M, Harvey NC, Lorentzon M, Leslie WD & Kanis JA (2023) A Meta-Analysis of Previous Falls and Subsequent Fracture Risk. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 242-242)
  • McCloskey E, Johansson H, Harvey N, Liu E, Schini M, Vandenput L, Lorentzon M, Leslie W & Kanis J (2023) Previous Fracture and Subsequent Fracture Risk: A Meta-analysis to Update FRAX. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 57-57)
  • Harvey N, Johansson H, McCloskey E, Liu E, Schini M, Vandenput L, Lorentzon M, Leslie W & Kanis J (2023) The Association Between Body Mass Index and Fracture is Dependent on Femoral Neck BMD: An International Meta-Analysis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 166-166)
  • Tan A, McCloskey E, Zheng Z, Harvey N, Lorentzon M, Kanis J & Schini M (2023) Medications, Fracture Risk and Oral Bisphosphonate Efficacy - Evidence from a Well-Characterized Prospective Clinical Trial in Older Women. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 63-63)
  • McCloskey E, Johansson H, Harvey N, Liu E, Schini M, Vandenput L, Lorentzon M, Leslie W & Kanis J (2023) Parental History of Hip Fracture and Future Fracture Risk: an International Meta-analysis to Inform Updates of FRAX. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 345-345)
  • Gandham A, Gregori G, Johansson L, Johansson H, Harvey N, Vandenput L, McCloskey E, Kanis J, Schini M, Litsne H , Axelsson K et al (2023) Sarcopenia definitions And their Association with Non-fracture injurious Falls in older Swedish women From the SUPERB study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 386-386)
  • McCloskey EV, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, Leslie WD, Schini M & Kanis JA (2023) FRAXPLUS-POST HOC EXPLORATION OF IMPACT OF ADDITIONAL RISK FACTOR INFORMATION ON FRAX PROBABILITY CALCULATIONS. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S52-S52)
  • Johansson H, Albergaria BH, Zerbini CA, Vilaca T, Harvey NC, Enwu E, Vandenput L, Lorentzon M, Schini M, Mccloskey E & Kanis JA (2023) CHANGES IN HIP FRACTURE INCIDENCE IN BRAZIL AND IMPLICATIONS FOR FRAX. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S268-S269)
  • Schini M, Kanis J, Johansson H, Harvey N, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorenzon M, Liu E, Vandenput L & Mccloskey E (2023) ADJUSTING CONVENTIONAL FRAX ESTIMATES OF FRACTURE PROBABILITY ACCORDING TO THE NUMBER OF PRIOR FRACTURES. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S57-S57)
  • Johansson H, Latt TS, Chit TT, Chandran M, Schini M, Liu E, Lorentzon M, Vandenput L, Harvey NC, Mccloskey E & Kanis JA (2023) A SURROGATE FRAX MODEL FOR MYANMAR. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S270-S271)
  • Johansson H, Messina OD, Vidal M, Neira LFV, Liu E, Lorentzon M, Vandenput L, Schini M, Harvey NC, Mccloskey E & Kanis JA (2023) A SURROGATE FRAX MODEL FOR PERU. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S269-S269)
  • Schini M, Peel N, Toronjo-Urquiza L, Thomas E, Salam S, Khwaja A, Eastell R & Walsh J (2022) . Journal of Bone and Mineral Research, Vol. 37(S1) (pp S271-S271). San Diego, California, 1 October 2021 - 1 October 2021.
  • Mattia L, Mark-Wagstaff C, Abrahamsen B, Davis S, Peel N, Eastell R & Schini M (2022) Monitoring Bisphosphonate Treatment In Primary Care: PINP And Osteoporosis In Sheffield Evaluation (POSE Study). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 64-65)
  • Schini M, Peel N, Toronjo-Urquiza L, Thomas E, Salam S, Khwaja A, Eastell R & Walsh J (2021) RENAL SAFETY OF ZOLEDRONIC ACID IN PATIENTS WITH BORDERLINE KIDNEY FUNCTION AT A METABOLIC BONE CENTRE IN THE UK. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S194-S195)
  • Mattia L, Mark-Wagstaff C, Abrahamsen B, Davis S, Peel N, Eastell R & Schini M (2021) MONITORING BISPHOSPHONATE TREATMENT IN PRIMARY CARE: PINP AND OSTEOPOROSIS IN SHEFFIELD EVALUATION (POSE STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S288-S288)
  • Vilaca T, Schini M, Harnan S, Poku E, Cummings SR & Eastell R (2020) . Journal of the Endocrine Society, Vol. 4(Supplement_1). San Francisco, CA, USA, 28 March 2020 - 28 March 2020.
  • Schini M, Vilaca T, Poku E, Harnan S, Sutton A, Allen IE, Cummings S & Eastell R (2020) THE RISK OF HIP AND NON-VERTEBRAL FRACTURES IN PARKINSON'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S55-S55)
  • Schini M, Jacques R, Oakes E, Peel N, Walsh J & Eastell R (2020) NORMOCALCEMIC HYPERPARATHYROIDISM: STUDY OF THE PREVALENCE AND NATURAL HISTORY. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S192-S192)
  • Schini M, Jacques R, Oakes E, Peel N, Walsh J & Eastell R (2020) Normocalcaemic hyperparathyroidism (NPHPT) and primary hyperparathyroidism (PHPT): Least significant change (LSC) for adjusted serum calcium. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 55-55)
  • Schini M, Vilaca T, Eastell R, Harnan S, Sutton A, Poku E & Cummings S (2019) The Risk of Hip and Non-Vertebral Fractures in Parkinson's Disease: A Systematic Review and Meta-Analysis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 103-103)
  • Vilaca T, Salam S, Eastell R, Schini M, Harnan S, Sutton A, Poku E & Cummings S (2019) The Risk of Hip and Non-Vertebral Fractures in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 25-25)
  • Schini M & Eastell R (2018) . Osteoporosis International, Vol. 29 (pp 632-633). Birmingham, UK, 2 December 2018 - 2 December 2018.
  • Schini M, Jacques R, Peel N, Walsh J & Eastell R (2018) Normocalcaemic Hyperparathyroidism: Study Of The Prevalence And Natural History In A United Kingdom Referral Population. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 129-129)
  • Schini M, Jacques R, Peel N, Walsh J & Eastell R (2018) NORMOCALCAEMIC HYPERPARATHYROIDISM: STUDY OF THE PREVALENCE AND NATURAL HISTORY IN A UNITED KINGDOM REFERRAL POPULATION. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp 627-627)
  • Schini M, Jacques R, Peel N, Walsh J & Eastell R (2016) NORMOCALCAEMIC HYPERPARATHYROIDISM: PREVALENCE IN A UNITED KINGDOM REFERRAL POPULATION. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp 649-650)
  • Manolakopoulos S, Schini M, Deutsch M, Triantos CK, Meal M, Striki A, Karafatelli M, Tzourmakliotis D & Papatheodoridis GV (2010) ABSOLUTE NEUTRIPHIL COUNT IS NOT ASSOCIATED WITH THE DEVELOPMENT OF INFECTIONS IN PATIENTS WITH HCV HEPATITIS RECEIVING ANTI VIRAL TREATMENT. HEPATOLOGY, Vol. 52(4) (pp 807A-807A)
  • Barrett-Connor E, Black D, Bonjour JP, Dequeker J, Ehrlich GE, Eis SR, Genant HK, Gennari C, Johnell O, Kanis J , Liberman UA et al (2003) Prevention and management of osteoporosis : report of a WHO scientific group. World Health Organization - Technical Report Series(921). Geneva, Switzerland
Teaching interests

I am engaged in various teaching sessions for undergraduate and postgraduate students and have supervised a number of research placement students, including a CIMA MRes student and visiting clinical fellows.

Professional activities and memberships

I am a Fellow of the Higher Education Academy and a member of the Association of Medical Educators.

Current projects

  • The use of PINP in a primary care setting to monitor osteoporosis (the POSE Study)

This is a project that I lead on and involves the assessment of a bone marker called PINP in a real-life setting in order to check whether patients that are monitored using this marker have better outcomes in terms of bone density, number of fractures and treatment persistence than the patients not monitored. This project is in collaboration with ScHARR and Professor Bo Abrahamsen in Denmark and has received a grant funding by Roche Diagnostics.

  • Osteoclast precursors in patients treated with denosumab

Denosumab is an anti-osteoporotic medication that has proven effective in preventing bone loss and reducing the incidence of fractures. However, on discontinuation of denosumab there is a rebound of bone turnover to 200% of pre-treatment baseline, which is associated with loss of the comparative gains in bone strength, and concerns have arisen amid cases reporting an increase in the incidence of osteoporotic fractures. The aim of this project, is to investigate the effect of denosumab on the osteoclast precursor population in order to elucidate the cellular mechanisms of this phenomenon.

  • Neutrophil migratory function in patients treated with zoledronic acid

Both statins and zoledronic acid target the same metabolic pathway, therefore we suspect the mechanism underlying the reduction in morbidity and mortality in patients with zoledronic acid may be related to an ameliorated function of neutrophils. This is an early stage study, aiming to see what the effect of zoledronic acid is on the migratory function of neutrophils and their ability to engulf and destroy bacteria.

Links